Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NF135.C10 Sporozoite Immunization for Malaria
NCT03813108Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2019
- Primary completion
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of PfSPZ Challenge (NF135.C10) in malaria (7 arms), sponsored by Radboud University Medical Center. Primary endpoints: Frequency of Adverse Events After NF135.C10 CPS Immunization at 35 weeks and Magnitude of Adverse Events After NF135.C10 CPS Immunization at 35 weeks. Started Apr 2019; status: terminated.
02
Drugs
PfSPZ Challenge (NF135.C10)
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03813108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813108.